Securities code: 300871 securities abbreviation: Hvsen Biotechnology Co.Ltd(300871) Announcement No.: 2022-005 convertible bond Code: 123132 convertible bond abbreviation: Huisheng convertible bond
Hvsen Biotechnology Co.Ltd(300871)
Announcement on adjusting the amount and period of idle raised funds and self owned funds for cash management. The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
The 22nd Meeting of the second board of directors and the 19th meeting of the second board of supervisors held by Hvsen Biotechnology Co.Ltd(300871) (hereinafter referred to as “the company”) on January 21, 2022 considered and adopted the proposal on adjusting the amount and period of cash management using idle raised funds and self owned funds. Independent directors expressed their independent opinions on the proposal. This matter falls within the decision-making authority of the board of directors of the company and does not need to be submitted to the general meeting of shareholders for deliberation.
According to the operation of the company, in order to further improve the use efficiency of funds and cash management income, without affecting the construction and daily production and operation of the company’s raised investment projects, The company plans to increase the amount of cash management with idle raised funds from the original no more than RMB 200 million (including this amount, the same below) to RMB 250 million (including the funds raised by the initial public offering of shares in August 2020 and the funds raised by the issuance of convertible corporate bonds to unspecified objects in December 2021), The amount of cash management using idle self owned funds will be increased from no more than RMB 100 million to RMB 200 million. After adjustment, the company’s total cash management limit is RMB 45 million, which is valid within 12 months from the date of deliberation and approval by the board of directors. Within the above limit and validity period, the funds can be recycled and used in a rolling manner. The details are hereby announced as follows:
1、 Basic information of raised funds
(I) funds raised by initial public offering
1. Actual raised fund amount and fund arrival time
According to the reply on Approving the registration of Hvsen Biotechnology Co.Ltd(300871) initial public offering (zjxk [2020] No. 1586) of China Securities Regulatory Commission, the company publicly issued 27700000 RMB common shares to the public in August 2020, with a par value of 1.00 yuan per share, an issue price of 33.61 yuan per share and a total raised capital of 930997000.00 yuan, The raised capital after deducting 63367726.39 yuan of recommendation and underwriting fee (excluding tax) paid is 867629273.61 yuan. In addition, after deducting 16916752.81 yuan of issuance expenses excluding tax such as audit and verification fees, lawyer fees, information disclosure fees and notarization fees, the net amount of raised funds is 850712520.80 yuan. All the above raised funds were received on August 17, 2020 and verified by Zhongshen Zhonghuan Certified Public Accountants (special general partnership), and a capital verification report of Zhonghuan Yanzi [2020] No. 010051 was issued. The company adopts special account storage management for the raised funds.
2. Investment plan of raised funds
The plan for the use of the net funds raised by the company’s initial public offering is as follows:
Unit: 10000 yuan
No. project name total investment raised funds
Investment amount
1. Construction project of powder / powder / premix automatic production base 32000.00 32000.00 Xingou base
2. R & D and quality inspection center construction project 7000.00 7000.00
3. Construction project of 1600t / a tylosin fermentation production base 7000.00 7000.00
4. Construction project of traditional Chinese medicine extraction and preparation production line 6000.00 6000.00
5. Supplementary working capital 7000.00 7000.00
6. Over raising: tylosin project with an annual output of 1000 tons 38000.00 26071.25
Total 97000.00 85071.25
(II) issuing convertible corporate bonds to unspecified objects to raise funds
1. Actual raised fund amount and fund arrival time
With the approval of the China Securities Regulatory Commission on the registration of Hvsen Biotechnology Co.Ltd(300871) issuing convertible corporate bonds to unspecified objects (zjxk [2021] No. 3570), the company issued 7 million convertible corporate bonds to unspecified objects, each with a face value of 100 yuan and a total raised capital of 700 million yuan. After deducting the underwriting recommendation fee of RMB 8556603.77 (excluding tax) from the issuance of convertible corporate bonds to unspecified objects, the raised funds of RMB 691443396.23 were transferred to the special storage account of raised funds designated by the company on December 23, 2021. After deducting the underwriting and recommendation fees, audit and capital verification fees, lawyer fees, credit rating fees and other expenses totaling 10700982.87 yuan (excluding tax), the total amount of funds raised from the issuance of convertible corporate bonds to unspecified objects is 689299017.13 yuan. On December 23, 2021, Zhongshen Zhonghuan Certified Public Accountants (special general partnership) issued the verification report on the raised funds from Hvsen Biotechnology Co.Ltd(300871) issuance of convertible corporate bonds (Zhonghuan Yan Zi [2021] No. 0100097), which verified and confirmed the paid in of the above raised funds.
2. Investment plan of raised funds
The company issues convertible corporate bonds to unspecified objects, and the raised funds shall be invested in the following items after deducting the issuance related expenses:
Unit: 10000 yuan
No. project name total investment amount raised capital investment amount
1. Expansion project of tylosin production line with an annual output of 1000 tons and tylosin production line with an annual output of 600 tons 33324.08 28500.00
2 Hubei Huisheng preparation production line automation comprehensive reconstruction and expansion project 13882.07 12100.00
3 pet preparation comprehensive production line construction project 9996.92 9000.00
4 powder / premix production line expansion project 6358.05 4900.00
5. Supplementary working capital 15500.00 15500.00
Total 79061.12 70000.00
2、 Use and balance of raised funds
(I) as of December 31, 2021, the use and balance of funds raised by the company’s initial public offering are as follows:
Project amount (RMB)
Net proceeds received in 2020: 850712520.80
Plus: interest income deducting handling fee 8774375.26
Financial income from idle raised funds 2860058.38
Less: 631023193.29 accumulated investment in projects invested with raised funds
Including: construction project of powder / powder / premix automatic production base in Xingou base 218708751.33
Xingou base R & D and quality inspection center construction project 56555068.95
Construction project of 1600t / a tylosin fermentation production base 69973144.47
Traditional Chinese medicine extraction and preparation production line construction project 60086012.56
Over raised funds: 225700215.98 of tylosin project with an annual output of 1000 tons
Supplementary working capital 70000000.00
As of December 31, 2021, the balance of the special account for raised funds was 161323761.15
(II) as of December 31, 2021, the company issued convertible corporate bonds to unspecified objects, and the use and balance of the collected funds are as follows:
Project amount (RMB)
Total raised funds 700 million.00
Less: underwriting recommendation fee 8556603.77
Amount of funds received 691443396.23
Plus: interest income deducting handling fee 264592.34
As of December 31, 2021, the balance of the special account for raised funds was 691707988.57
Note: as of December 31, 2021, the difference between the balance of the special account for raised funds and the net amount of funds raised from the issuance of convertible corporate bonds to unspecified objects is due to the use of self raised funds to invest in raised investment projects in advance and the fact that some of the paid issuance expenses have not been replaced
As of December 31, 2021, the balance of funds raised by the company’s initial public offering of shares in 2020 was 161.3238 million yuan (including interest income and financial management income), and the balance of funds raised by the company’s issuance of convertible corporate bonds to unspecified objects in 2021 was 69.1708 million yuan (including interest income). The above-mentioned unused raised funds totaled 853.0318 million yuan, all of which were deposited in the special account for raised funds.
Comprehensively considering the subsequent fund use plan for the construction of relevant raised investment projects, in order to improve the use efficiency and investment return of raised funds, the company plans to increase the amount of temporarily idle raised funds for cash management.
3、 Previous use of some idle raised funds and self owned funds for cash management
The proposal on using some idle raised funds for cash management and the proposal on using idle self owned funds for entrusted financial management adopted by the fifth extraordinary general meeting of shareholders in 2020 held on September 28, 2020 agree that the company will not affect the raised funds
